X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (96) 96
adult (68) 68
male (68) 68
female (54) 54
pharmacology & pharmacy (54) 54
middle aged (53) 53
pharmacokinetics (52) 52
hiv infections - drug therapy (43) 43
infectious diseases (35) 35
drug therapy, combination (34) 34
ritonavir (34) 34
drug interactions (33) 33
anti-hiv agents - pharmacokinetics (32) 32
index medicus (32) 32
hiv protease inhibitors - pharmacokinetics (28) 28
immunology (27) 27
virology (25) 25
anti-hiv agents - administration & dosage (24) 24
cross-over studies (23) 23
reverse transcriptase inhibitors - pharmacokinetics (23) 23
safety (23) 23
efficacy (22) 22
adolescent (21) 21
darunavir (20) 20
hiv-1 (20) 20
protease inhibitors (20) 20
anti-hiv agents - therapeutic use (19) 19
antiretroviral therapy (19) 19
hiv (19) 19
ritonavir - pharmacokinetics (19) 19
area under curve (18) 18
hiv protease inhibitors - therapeutic use (18) 18
ritonavir - administration & dosage (18) 18
etravirine (17) 17
hiv protease inhibitors - administration & dosage (17) 17
pyridazines - pharmacokinetics (17) 17
reverse transcriptase inhibitors - therapeutic use (17) 17
young adult (17) 17
anti-hiv agents - adverse effects (16) 16
hiv protease inhibitors - blood (16) 16
research (16) 16
reverse transcriptase inhibitors - administration & dosage (16) 16
anti-hiv agents - blood (15) 15
drug administration schedule (15) 15
sulfonamides - pharmacokinetics (15) 15
double-blind (14) 14
hiv infections - blood (14) 14
hiv infections - virology (14) 14
indinavir (14) 14
placebo-controlled trial (14) 14
treatment outcome (14) 14
experienced hiv-1-infected patients (13) 13
tmc125 etravirine (13) 13
dosage and administration (12) 12
dose-response relationship, drug (12) 12
hiv infection (12) 12
hiv-1 - drug effects (12) 12
nevirapine (12) 12
pyridazines - administration & dosage (12) 12
pyridazines - adverse effects (12) 12
rna, viral - blood (12) 12
saquinavir (12) 12
hiv infections - metabolism (11) 11
microbiology (11) 11
sulfonamides - administration & dosage (11) 11
sulfonamides - adverse effects (11) 11
administration, oral (10) 10
antiviral agents (10) 10
drug monitoring (10) 10
drug therapy (10) 10
hiv protease inhibitors - adverse effects (10) 10
hiv-1 - genetics (10) 10
infection (10) 10
nevirapine - pharmacokinetics (10) 10
pharmacology (10) 10
plasma (10) 10
resistance (10) 10
ritonavir - adverse effects (10) 10
stavudine - therapeutic use (10) 10
time factors (10) 10
viral load (10) 10
zidovudine (10) 10
biological availability (9) 9
cd4 lymphocyte count (9) 9
healthy volunteers (9) 9
lamivudine - therapeutic use (9) 9
reverse transcriptase inhibitors - adverse effects (9) 9
reverse transcriptase inhibitors - blood (9) 9
saquinavir - therapeutic use (9) 9
biochemical research methods (8) 8
chemistry, analytical (8) 8
non-nucleoside reverse transcriptase inhibitor (8) 8
saquinavir - administration & dosage (8) 8
saquinavir - pharmacokinetics (8) 8
therapy (8) 8
tmc125 (8) 8
toxicology (8) 8
efavirenz (7) 7
hiv seronegativity (7) 7
human immunodeficiency virus--hiv (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 10/2014, Volume 69, Issue 10, p. 2591
  The ability to dose antiretroviral agents once daily simplifies the often complex therapeutic regimens required for the successful treatment of HIV... 
Protease inhibitors | Human immunodeficiency virus--HIV | Pharmacology | Drug dosages | Clinical outcomes
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 03/2014, Volume 65, Issue 3, p. 283
  TMC310911 is a novel HIV type-1 (HIV-1) protease inhibitor with broad in vitro antiviral activity. In this phase 2a, open-label randomized study, the... 
Antiretroviral drugs | Protease inhibitors | Human immunodeficiency virus--HIV | Medical treatment | Ribonucleic acid--RNA
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 1/2011, Volume 50, Issue 1, pp. 25 - 39
Etravirine (formerly TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against wild-type and NNRTI-resistant strains of HIV-1.... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Drug-interactions | Ribavirin, drug interactions | Antiepileptic-drugs, drug interactions | Simvastatin, drug interactions | Voriconazole, drug interactions | Dexamethasone, drug interactions | Fibric-acid-derivatives, drug interactions | Rifampicin, drug interactions | Opioid-analgesics, drug interactions | Antidepressants, drug interactions | Atorvastatin, drug interactions | Antiretrovirals, drug interactions | Anti-infectives, drug interactions | Histamine-H2-receptor-antagonists, drug interactions | Diazepam, drug interactions | Ketoconazole, drug interactions | Fluconazole, drug interactions | Hypericum, drug interactions | HMG-CoA-reductase-inhibitors, drug interactions | Oral-contraceptives, drug interactions | Sildenafil, drug interactions | Omeprazole, drug interactions | Buprenorphine, drug interactions | Rosuvastatin, drug interactions | Non-nucleoside-reverse-transcriptase-inhibitors, drug interactions | Type-5-cyclic-nucleotide- phosphodiesterase-inhibitors, drug interactions | Corticosteroids, drug interactions | Paroxetine, drug interactions | Fluoxetine, drug interactions | Rifapentine, drug interactions | Ethinylestradiolnorethisterone, drug interactions | Ranitidine, drug interactions | Etravirine, drug interactions | Antifungals, drug interactions | Digoxin, drug interactions | Warfarin, drug interactions | Methadone, drug interactions | Fluvastatin, drug interactions | Rifabutin, drug interactions | Sertraline, drug interactions | Azithromycin, drug interactions | Pharmacokinetics | Calcineurin-inhibitors, drug interactions | Itraconazole, drug interactions | Proton-pump-inhibitors, drug interactions | Clarithromycin, drug interactions | TRANSCRIPTASE INHIBITOR ETRAVIRINE | METABOLISM | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | HIV-NEGATIVE VOLUNTEERS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | HUMAN LIVER | PLACEBO-CONTROLLED TRIAL | 2 DIFFERENT FORMULATIONS | CLINICAL PHARMACOKINETICS | Reverse Transcriptase Inhibitors - adverse effects | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | Drug-Related Side Effects and Adverse Reactions | Humans | Pyridazines - pharmacokinetics | Drug Therapy, Combination | Pyridazines - adverse effects | Etravirine | Drug interactions | Physiological aspects | Dosage and administration | Research | Properties | Drug therapy | HIV infection
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 08/2014, Volume 54, Issue 8, pp. 949 - 957
This study compared the bioavailability of two candidate fixed‐dose combinations (FDCs: G003 and G004) of darunavir/cobicistat 800/150 mg with that of... 
fixed‐dose combination | darunavir | cobicistat | bioavailability | pharmacoenhancer | fixed-dose combination | EFFICACY | SAFETY | HIV-1-INFECTED PATIENTS | ANTIRETROVIRAL THERAPY | PROTEASE INHIBITORS | TREATMENT-NAIVE | HIV | TREATMENT-EXPERIENCED PATIENTS | PHARMACOLOGY & PHARMACY | LOPINAVIR/RITONAVIR | ONCE-DAILY DARUNAVIR/RITONAVIR | Thiazoles - blood | Darunavir | Humans | Middle Aged | Biological Availability | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Healthy Volunteers | Carbamates - pharmacokinetics | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Young Adult | Sulfonamides - blood | Ritonavir - adverse effects | HIV Protease Inhibitors - pharmacokinetics | Adult | Female | HIV Protease Inhibitors - adverse effects | HIV Protease Inhibitors - blood | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - blood | Ritonavir - administration & dosage | Ritonavir - blood | Carbamates - blood | HIV Protease Inhibitors - administration & dosage | Sulfonamides - pharmacokinetics | Cross-Over Studies | Ritonavir - pharmacokinetics | Sulfonamides - adverse effects | Carbamates - adverse effects | Cytochrome P-450 CYP3A Inhibitors - adverse effects | Cobicistat | Drug Combinations | Sulfonamides - administration & dosage | Usage | Dosage and administration | Drug therapy, Combination | Pharmacokinetics | Analysis | Short term
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 12/2008, Volume 52, Issue 12, pp. 4228 - 4232
Journal Article
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 08/2013, Volume 53, Issue 8, pp. 834 - 840
Journal Article
Journal Article
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 02/2014, Volume 54, Issue 2, pp. 133 - 140
Antiretrovirals may influence methadone exposure in HIV‐1‐infected patients receiving methadone for opiate addiction. Rilpivirine is a non‐nucleoside reverse... 
pharmacokinetics | non‐nucleoside reverse transcriptase inhibitor | methadone | rilpivirine | Non-nucleoside reverse transcriptase inhibitor | Methadone | Pharmacokinetics | Rilpivirine | DRUG-INTERACTIONS | (R)-METHADONE | PHARMACODYNAMICS | OPIATE WITHDRAWAL | PHASE-3 | THRIVE | METABOLISM | PLASMA-CONCENTRATIONS | EFAVIRENZ | PHARMACOLOGY & PHARMACY | non-nucleoside reverse transcriptase inhibitor | RITONAVIR | Anti-HIV Agents - pharmacology | Opioid-Related Disorders - drug therapy | Nitriles - pharmacology | Humans | Middle Aged | Substance Withdrawal Syndrome - drug therapy | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Young Adult | Drug Therapy, Combination - adverse effects | Drug Interactions | Analgesics, Opioid - chemistry | Adult | Methadone - pharmacokinetics | Volunteers | HIV Seronegativity | Methadone - blood | Analgesics, Opioid - blood | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Pyrimidines - pharmacology | Methadone - chemistry | Opiate Substitution Treatment - adverse effects | Analgesics, Opioid - administration & dosage | Adolescent | Analgesics, Opioid - pharmacokinetics | Pyrimidines - adverse effects | Methadone - adverse effects | Nitriles - adverse effects | Methadone hydrochloride | Dosage and administration | Research | Confidence intervals | Substance abuse treatment | Human immunodeficiency virus--HIV
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 10/2008, Volume 66, Issue 4, pp. 508 - 516
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 03/2014, Volume 69, Issue 3, pp. 728 - 734
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 05/2014, Volume 54, Issue 5, pp. 563 - 573
Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) may require treatment with an HIV non‐nucleoside reverse transcriptase... 
etravirine | pharmacokinetics | non‐nucleoside reverse transcriptase inhibitor | drug–drug interaction | telaprevir | rilpivirine | drug-drug interaction | non-nucleoside reverse transcriptase inhibitor | EFFICACY | SAFETY | LIVER FIBROSIS | PHASE-3 | HUMAN-IMMUNODEFICIENCY-VIRUS | THRIVE | HEPATITIS-C VIRUS | HIV | EFAVIRENZ | PHARMACOLOGY & PHARMACY | INFECTION | Anti-HIV Agents - pharmacology | Nitriles - pharmacology | Reverse Transcriptase Inhibitors - blood | Pyrimidines - blood | Rilpivirine | Humans | Middle Aged | Reverse Transcriptase Inhibitors - pharmacology | Male | Pyridazines - pharmacology | Healthy Volunteers | Oligopeptides - adverse effects | Nitriles - pharmacokinetics | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | Adult | Female | Anti-HIV Agents - blood | Pyridazines - adverse effects | Oligopeptides - blood | Anti-HIV Agents - adverse effects | Oligopeptides - pharmacokinetics | Pyrimidines - pharmacology | Cross-Over Studies | Pyridazines - blood | Anti-HIV Agents - pharmacokinetics | Adolescent | Pyrimidines - adverse effects | Nitriles - blood | Pyrimidines - pharmacokinetics | Pyridazines - pharmacokinetics | Nitriles - adverse effects | Oligopeptides - pharmacology | Evaluation | Drug interactions | Etravirine | Influence | Research | Pharmacokinetics
Journal Article